D
Daliya Kancheva
Researcher at Janssen Pharmaceutica
Publications - 2
Citations - 249
Daliya Kancheva is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Fusion protein & CCR8. The author has an hindex of 2, co-authored 2 publications receiving 44 citations.
Papers
More filters
Journal ArticleDOI
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.
Ana Rita Pombo Antunes,Isabelle Scheyltjens,Francesca Lodi,Julie Messiaen,Asier Antoranz,Johnny Duerinck,Daliya Kancheva,Liesbet Martens,Karen De Vlaminck,Hannah Van Hove,Signe Schmidt Kjølner Hansen,Francesca Maria Bosisio,Koen Van der Borght,Steven De Vleeschouwer,Steven De Vleeschouwer,Raf Sciot,Luc Bouwens,M. Verfaillie,Niels Vandamme,Roosmarijn E. Vandenbroucke,Olivier De Wever,Yvan Saeys,Martin Guilliams,Conny Gysemans,Bart Neyns,Frederik De Smet,Diether Lambrechts,Jo A. Van Ginderachter,Kiavash Movahedi +28 more
TL;DR: This article employed single-cell RNA sequencing and CITE-seq to map the glioblastoma immune landscape in mouse tumors and in patients with newly diagnosed disease or recurrence.
Journal ArticleDOI
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.
Helena Van Damme,Bruno Dombrecht,Mate Kiss,Heleen Roose,Elizabeth Allen,Eva Van Overmeire,Daliya Kancheva,Liesbet Martens,Aleksandar Murgaski,Pauline M. R. Bardet,Gillian Blancke,Maude Jans,Evangelia Bolli,Maria Solange Martins,Yvon Elkrim,James Dooley,Louis Boon,Julia Katharina Schwarze,Frank Tacke,Kiavash Movahedi,Niels Vandamme,Bart Neyns,Sebahat Ocak,Isabelle Scheyltjens,Lars Vereecke,Frank Aboubakar Nana,Pascal Merchiers,Damya Laoui,Jo A. Van Ginderachter +28 more
TL;DR: In this paper, two CCR8-specific nanobodies (Nbs) were formulated as tetravalent Nb-Fc fusion proteins for optimal binding and blocking, containing either an antibody-dependent cell-mediated cytotoxicity (ADCC)-deficient or an ADCC-prone Fc region.